Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The clininal significance of identification technique of trifluridine incorporated into DNA in colorectal cancer patients treated with trifluridine / tipiracil.( KSCC 1602-A)

Next Previous
X
Search
Trial Profile

The clininal significance of identification technique of trifluridine incorporated into DNA in colorectal cancer patients treated with trifluridine / tipiracil.( KSCC 1602-A)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KSCC 1602-A

    • Most Recent Events

    • 07 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 06 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top